Biosimilars

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product. They are developed to have the same mechanism of action, route of administration, dosage form, and strength as the reference product. Biosimilars are not generic drugs, as they are derived from living organisms and their production involves complex manufacturing processes. The introduction of biosimilars in the market can increase competition, potentially leading to reduced costs and increased access to biological therapies for patients. Despite their similarities, biosimilars and their reference products may have minor differences in inactive components.

    Related Conference of Biosimilars

    August 18-19, 2025

    40th World Congress on Pharmacology and Therapeutics

    Valencia, Spain
    September 19-20, 2025

    18th World Drug Delivery Summit

    Paris, France
    September 22-23, 2025

    Pharma Biotech Expo

    Toronto, Canada
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 13-14, 2025

    21st International Conference on Pharmaceutical Chemistry

    Aix-en-Provence, France
    November 20-21, 2025

    21st Annual Congress on Pharmacology and Toxicology

    Paris, France
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    13th International Conference on Clinical Trials

    Amsterdam, Netherlands
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, Aland Islands
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands

    Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in